Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
1960s
|
| gptkbp:ATCCode |
N03AD01
|
| gptkbp:brand |
ethosuximide
|
| gptkbp:chemicalClass |
succinimide anticonvulsant
|
| gptkbp:eliminationHalfLife |
30-60 hours
|
| gptkbp:form |
gptkb:sugar
capsule |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:mechanismOfAction |
reduces T-type calcium currents in thalamic neurons
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting loss of appetite drowsiness |
| gptkbp:usedFor |
epilepsy
absence seizures |
| gptkbp:bfsParent |
gptkb:Ethosuximide
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zarontin
|